Valuation: StemRIM

Market Cap 7.65B 48.01M 43.58M 40.26M 36.32M 68.56M 4.49B 71.19M 485M 192M 2.42B 180M 176M P/E 2025
-10.2x
P/E 2026 -10.1x
Enterprise Value 2.27B 14.25M 12.94M 11.95M 10.78M 20.35M 1.33B 21.13M 144M 56.96M 718M 53.47M 52.34M EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
46.29%
Yield 2025 *
-
Yield 2026 -
11-09 StemRIM Inc. Announces Patent Registration in Australia for Redasemtide as Additional Therapeutic Indication for Fatty Liver and Non-Alcoholic Steatohepatitis CI
11-09 StemRIM Inc. Announces Patent Registration In Israel For Redasemtide As Therapeutic Agent For Cartilage Disorder CI
10-07 StemRIM Inc. Announces Patent Registration for Stem Cell Gene Therapy Technology SR-GT1 Aimed at Curative Treatment of Dystrophic Epidermolysis Bullosa in USA CI
09-25 StemRIM Inc. Announces Patent Registration In South Korea For Use Of Redasemtide As Additional Therapeutic Indication Of Cartilage Disorders CI
09-09 StemRIM Reports Earnings Results for the Full Year Ended July 31, 2026 CI
07-22 Stemrim Announces Patent Registration in Mexico for Redasemtide as Therapeutic Agent for Cartilage Disorders CI
07-08 StemRIM Inc. Announces Patent Registration For Stem Cell Gene Therapy Technology SR-GT1 Aimed At Curative Treatment Of Dystrophic Epidermolysis Bullosa In South Korea CI
06-17 StemRIM Announces Patent Registration for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders CI
06-16 StemRIM Inc Announces Patent Registration In Russia For Redasemtide As Therapeutic Drug For Fatty Liver And Non-Alcoholic Steatohepatitis CI
06-16 StemRIM to Register Russian Patent of Drug Candidate for Fatty Liver Disease MT
06-10 StemRIM Reports Earnings Results for the Nine Months Ended April 30, 2026 CI
05-12 Stemrim Inc. Announces Progress for Regeneration-Inducing Medicine Redasemtide CI
04-15 StemRIM Finishes Enrollment in Phase 1/2 Redasemtide Study MT
1 day+0.82%
1 week+3.36%
Current month-11.51%
1 month-22.64%
3 months-64.66%
6 months-57.59%
Current year-53.23%
1 week 114
Extreme 114
128
1 month 110
Extreme 110
163
Current year 110
Extreme 110
368
1 year 110
Extreme 110
368
3 years 110
Extreme 110
714
5 years 110
Extreme 110
1,518
10 years 110
Extreme 110
1,518
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 01/10/2022
Chief Executive Officer 58 25/10/2023
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 66 01/09/2026
Director/Board Member 58 01/03/2019
Director/Board Member 54 01/10/2019
Change 5-day change 1-year change 3-year change Capi.($)
+0.82%+3.36%-55.76%-81.70% 47.91M
-1.13%+0.25%+38.06%+140.43% 1,275B
-1.36%-1.21%+42.24%+85.68% 680B
-0.59%-0.16%+26.02%+111.76% 521B
-0.76%+1.27%+41.98%+71.50% 389B
-0.75%-3.62%+54.29%+40.57% 356B
-1.83%-0.13%+27.64%+60.13% 305B
-1.65%-1.88%+2.00%+35.77% 287B
-0.95%-1.57%+35.99%+70.23% 250B
+1.60%+0.56%+36.19%+128.48% 208B
Average -0.42%+0.97%+24.87%+66.29% 427B
Weighted average by Cap. -0.63%+0.76%+35.59%+96.15%

Financials

2025 2026
Net sales - -
Net income -1.93B -12.11M -10.99M -10.16M -9.16M -17.3M -1.13B -17.96M -122M -48.4M -611M -45.44M -44.48M -1.85B -11.62M -10.55M -9.74M -8.79M -16.6M -1.09B -17.23M -117M -46.44M -586M -43.6M -42.68M
Net Debt -6.99B -43.91M -39.86M -36.82M -33.22M -62.71M -4.1B -65.11M -444M -175M -2.21B -165M -161M -5.38B -33.76M -30.64M -28.31M -25.54M -48.21M -3.15B -50.06M -341M -135M -1.7B -127M -124M
Projected Income Statement - Annual - StemRIM
Logo StemRIM
StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Employees
48
Date Price Change Volume
18/11/26 ¥123.00 +0.82% 85,700
17/11/26 ¥122.00 0.00% 562,600
16/11/26 ¥122.00 +4.27% 718,500
13/11/26 ¥117.00 -1.68% 511,000
12/11/26 ¥119.00 0.00% 549,900
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - StemRIM
  1. Stock Market
  2. Stocks
  3. 4599 Stock